Congenital Hyperinsulinism International (CHI), a US-based 501(c)3 nonprofit organization, was founded in 2005 by an international group of concerned parents of children with congenital hyperinsulinism (HI). CHI’s mission is to improve the lives of people born with HI. A Scientific Advisory Group of HI clinicians and researchers make an important contribution to CHI’s work.
CHI supports research for better treatments and cures through its work with biotechs investigating new treatments, pilot grants for researchers, the HI Global Registry, a patient-powered research study, and the CHI Collaborative Research Network (CRN). The CRN includes HI community members working together to prioritize and execute an international research agenda. The research agenda focuses on understanding HI better, identifying new ways to improve the lives of those living with HI, reducing the incidence of irreversible brain damage, increasing knowledge of the genetic causes of HI types, and finding new treatments and cures for every type of HI.
CHI is also the foremost advocate for increased awareness and better medical protocols for HI to reduce preventable brain damage and death from prolonged hypoglycemia. Finally, CHI also works to improve access to genetic testing, lifesaving medication, and treatment for those with HI worldwide. CHI brings together the patient community, clinicians, researchers, and biotech industry members to achieve this work. For more information, visit https://congenitalhi.org.
